Literature DB >> 24793347

Association of nonalcoholic fatty liver disease with cardiovascular risk factors in obese adolescents: the role of interdisciplinary therapy.

Priscila L Sanches1, Aline de Piano2, Raquel M S Campos2, June Carnier2, Marco T de Mello3, Natália Elias4, Francisco A H Fonseca5, Deborah C L Masquio6, Patrícia L da Silva7, Flavia C Corgosinho2, Lian Tock8, Lila M Oyama9, Sergio Tufik10, Ana R Dâmaso11.   

Abstract

BACKGROUND: Obesity is associated with several cardiovascular risk factors, including nonalcoholic fatty liver disease (NAFLD). These risk factors can induce changes in the arteries such as an increase in the carotid intima-media thickness (cIMT), which contributes to the early development of atherosclerosis.
OBJECTIVE: To determine whether NAFLD is associated with an atherogenic lipid profile, inflammatory markers, or cIMT in obese adolescents and to compare the effects of therapeutic lifestyle changes in NAFLD and non-NAFLD groups.
METHODS: A total of 79 obese adolescents were divided into two groups: 33 NAFLD and 46 non-NAFLD. They were submitted to an interdisciplinary therapy involving diet exercise and psychological support during the course of 1 year. The cIMT and estimates of fat mass (liver, intra-abdominal, and subcutaneous) were determined ultrasonographically. Body composition, glucose, lipid profile, and adipokines were analyzed before and after the therapy.
RESULTS: At baseline, only in the NAFLD group was the homeostasis model assessment of insulin resistance positively correlated with cIMT and triglyceride/high-density lipoprotein cholesterol ratio. Therapy was associated with an increase in adiponectin concentrations and reduced visceral fat, cIMT, leptin, and plasminogen activator inhibitor-1 concentrations, as well as the ratios of total cholesterol/high-density lipoprotein cholesterol and triglycerides/high-density lipoprotein cholesterol in both groups. Only in the non-NAFLD group did therapy result in a reduction in the low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio and increased high-density lipoprotein cholesterol concentration.
CONCLUSIONS: In obese adolescents, NAFLD is associated with cardiovascular risk factors and inflammatory markers of atherosclerosis that were positively correlated with cIMT only in the NAFLD group. Nevertheless, the strength of the present study is that the interdisciplinary therapy effectively improved cIMT and other proinflammatory adipokines in both groups.
Copyright © 2014 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiovascular risk factors; Interdisciplinary intervention; Non-alcoholic fatty liver disease; Obesity

Mesh:

Substances:

Year:  2014        PMID: 24793347     DOI: 10.1016/j.jacl.2014.02.007

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  11 in total

Review 1.  Cardiometabolic risk in obese children.

Authors:  Stephanie T Chung; Anthony U Onuzuruike; Sheela N Magge
Journal:  Ann N Y Acad Sci       Date:  2018-01       Impact factor: 5.691

Review 2.  Nonmedicinal interventions in nonalcoholic fatty liver disease.

Authors:  Manuela G Neuman; Radu M Nanau; Lawrence B Cohen
Journal:  Can J Gastroenterol Hepatol       Date:  2015 Jun-Jul

3.  Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease.

Authors:  Jeffrey B Schwimmer; Michael S Middleton; Cynthia Behling; Kimberly P Newton; Hannah I Awai; Melissa N Paiz; Jessica Lam; Jonathan C Hooker; Gavin Hamilton; John Fontanesi; Claude B Sirlin
Journal:  Hepatology       Date:  2015-02-05       Impact factor: 17.425

4.  Factors early in life associated with hepatic steatosis.

Authors:  Sabrina Xin Zi Quek; Eunice Xiang-Xuan Tan; Yi Ping Ren; Mark Muthiah; Evelyn Xiu Ling Loo; Elizabeth Huiwen Tham; Kewin Tien Ho Siah
Journal:  World J Hepatol       Date:  2022-06-27

Review 5.  Lifestyle Interventions Including Nutrition, Exercise, and Supplements for Nonalcoholic Fatty Liver Disease in Children.

Authors:  Jonathan A Africa; Kimberly P Newton; Jeffrey B Schwimmer
Journal:  Dig Dis Sci       Date:  2016-04-04       Impact factor: 3.199

6.  Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease.

Authors:  Michael S Middleton; Mark L Van Natta; Elhamy R Heba; Adina Alazraki; Andrew T Trout; Prakash Masand; Elizabeth M Brunt; David E Kleiner; Edward Doo; James Tonascia; Joel E Lavine; Wei Shen; Gavin Hamilton; Jeffrey B Schwimmer; Claude B Sirlin
Journal:  Hepatology       Date:  2018-01-26       Impact factor: 17.425

7.  Differential TGFβ pathway targeting by miR-122 in humans and mice affects liver cancer metastasis.

Authors:  Shenyi Yin; Yu Fan; Hanshuo Zhang; Zhihua Zhao; Yang Hao; Juan Li; Changhong Sun; Junyu Yang; Zhenjun Yang; Xiao Yang; Jian Lu; Jianzhong Jeff Xi
Journal:  Nat Commun       Date:  2016-03-18       Impact factor: 14.919

8.  The Correlation and Risk Factors between Carotid Intima-Media Thickening and Alcoholic Liver Disease Coupled with Helicobacter pylori Infection.

Authors:  Qu Bao-Ge; Wang Hui; Jia Yi-Guo; Su Ji-Liang; Wang Zhong-Dong; Wang Ya-Fei; Han Xing-Hai; Liu Yuan-Xun; Pan Jin-Dun; Ren Guang-Ying
Journal:  Sci Rep       Date:  2017-02-21       Impact factor: 4.379

9.  Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: a real-life study.

Authors:  Valentina Guarnotta; Mariagrazia Irene Mineo; Stefano Radellini; Giuseppe Pizzolanti; Carla Giordano
Journal:  Ther Adv Endocrinol Metab       Date:  2019-08-28       Impact factor: 3.565

10.  [Waist circumference as a marker for screening nonalcoholic fatty liver disease in obese adolescents].

Authors:  Ana Paula Grotti Clemente; Bárbara Dal Molin Netto; Joana Pereira de Carvalho-Ferreira; Raquel Munhoz da Silveira Campos; Aline de Piano Ganen; Lian Tock; Marco Túlio de Mello; Ana Raimunda Dâmaso
Journal:  Rev Paul Pediatr       Date:  2015-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.